Home
GSC Advanced Research and Reviews
Peer-reviewed | Multidisciplinary Journal | Impact factor 8.3 | ISSN: 2582-4597 | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

Remifentanil as an anesthetic agent in children

Breadcrumb

  • Home
  • Remifentanil As An Anesthetic Agent In Children
  • Remifentanil as an anesthetic agent in children

Maria I Dalamagka *

Anesthesiology Department, General Hospital of Larisa, Greece.
 
Research Article
GSC Advanced Research and Reviews, 2024, 20(01), 001–004.
Article DOI: 10.30574/gscarr.2024.20.1.0238
DOI url: https://doi.org/10.30574/gscarr.2024.20.1.0238
Received on 19 May 2024; revised on 29 June 2024; accepted on 02 July 2024
 
Remifentanil hydrochloride is an ultra-short-acting opioid that undergoes rapid metabolism by tissue and plasma esterases. Remifentanil is increasingly used as an adjuvant to general anaesthesia in neonates undergoing surgery because of its favourable haemodynamic and respiratory effects compared with other agents. The pharmacokinetic profile of remifentanil appears well suited for use in the sedation of children for short, day case procedures and remifentanil has been demonstrated to be an attractive drug for this purpose. Owing to higher clearances, younger children will require higher infusion rates of remifentanil than older children and adults to achieve equivalent plasma concentrations. Propofol and remifentanil appear to be gaining popularity for short procedures in children. Together they provide sedation, anxiolysis and analgesia, possibly best provided by separate continuous infusions. They also promote haemodynamic stability, minimal respiratory depression, with a rapid recovery profile. The use of remifentanil in neonates and young infants is increasing despite the difficulties in obtaining high standard objective evidence in this age group. Remifentanil’s pharmacokinetic and pharmacodynamic profile in this age group is similar to that of older children, which may have several theoretical advantages. Reports of a rapid development of µ-receptor tolerance with remifentanil are in conflict; activity at δ-opioid receptors may contribute. Remifentanil produce a fall in blood pressure and cardiac index, mainly as a result of a fall in heart rate. Although atropine is able to reduce the fall in heart rate,  is not able to prevent  completely the reduction in cardiac index. Remifentanil has been described as a titratable opioid. It has been reported to be ideally suited to the sedation of selected neurosurgical patients who require frequent neurological examinations. It may also provide suitable analgesia based sedation in mechanically ventilated children postoperatively.
 
Remifentanyl; Anaesthesia; Sedation; Children; Surgery
 
https://gscarr.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCARR-2024-…

Preview Article PDF

Maria I Dalamagka. Remifentanil as an anesthetic agent in children. GSC Advanced Research and Reviews, 2024, 20(1), 001-004. Article DOI: https://doi.org/10.30574/gscarr.2024.20.1.0238

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 GSC Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution